[{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Megalith Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"RB-164","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radiance Biopharma","amount2":1.1699999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Radiance Biopharma \/ Radiance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Radiance Biopharma \/ Radiance Biopharma"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"RB-164","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radiance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"RB-164","moa":"ROR1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiance Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"YH012","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiance Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Radiance Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Radiance Biopharma \/ Radiance Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Radiance Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : RB-164 is an ROR-1 targeted antibody drug conjugate, which is currently being evaluated for the treatment of hematologic and solid malignancies.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          April 15, 2025

                          Lead Product(s) : RB-164

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : RB-164 is an ROR-1 targeted antibody drug conjugate, which is currently being evaluated for the treatment of hematologic and solid malignancies.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          March 31, 2025

                          Lead Product(s) : RB-164

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the licensing agreement, Radiance will be responsible for the development and commercialization of SYS6005 (RB-164), a novel clinical stage ADC targeting ROR-1 for treating neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : $15.0 million

                          February 19, 2025

                          Lead Product(s) : RB-164

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Megalith Pharmaceuticals

                          Deal Size : $1,165.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Radiance has an option to license YH012, a first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate from Biocytogen, for worldwide therapeutic development.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          August 01, 2024

                          Lead Product(s) : YH012

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Biocytogen

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank